Regeneron Pharmaceuticals, Inc.
Can Dupixent and the pipeline grow fast enough to replace the profit EYLEA loses to biosimilars before Dupixent itself faces patent expiry?
Last 4 earnings calls · through Q2 FY2026
Bull case
Dupixent franchise breadth
Dupixent keeps adding approved diseases and patients, so the collaboration profit Regeneron books from it grows even while the older eye drug shrinks.
Next-generation allergy antibodies
Long-acting allergy antibodies and broader talks with Sanofi could extend the immunology franchise well beyond Dupixent itself.
Cash returned to shareholders
High-margin collaboration profits and steady free cash flow fund both the pipeline and large buybacks, which raise earnings per share over time.
New products beyond eye care
Libtayo, cemdisiran and garetosmab give Regeneron several new products whose sales do not depend on the shrinking EYLEA franchise.
Bear case
EYLEA biosimilar erosion
The original EYLEA is losing sales to its own successor and to coming biosimilars, so retina revenue may keep falling faster than the newer product can grow.
Trial setbacks in oncology
Oncology programs have produced disappointing results, and rising research spending has not yet turned into approved products outside the core franchises.
Dupixent revenue concentration
A large share of Regeneron's revenue and profit comes from one Sanofi-partnered drug whose patent life management will not put a date on.
Manufacturing delays
Repeated holdups at outside fillers show that approval of key product improvements sits partly with contractors the company does not control.
Bull and bear points
Growth & Execution
In short: Dupixent, EYLEA HD and Libtayo are growing, while EYLEA declines and late-stage trial results have been mixed.
Dupixent growth driven by patient demand
Management attributes the second-quarter increase to demand across nine approved diseases, which means growth can continue as new indications and younger age groups are added.
Q2 FY2026 callEYLEA HD sales passed EYLEA for the first time
The conversion means Regeneron keeps most of its retina revenue as the older formulation declines, and physicians are steadily moving patients to the newer product.
Q2 FY2026 callSanofi talks now cover follow-on assets
A year ago management declined to comment on widening the Sanofi relationship; on this call it said early discussions are under way on Dupixent follow-on programs.
Tone shiftQ4 FY2025 → Q2 FY2026
Dupixent growth expected to moderate in second half
Management expects year-over-year growth to slow as recent launches annualize and comparisons get harder, so the largest profit contributor will add less each quarter.
Q2 FY2026 callFianlimab missed its primary endpoint
Management spent earlier calls describing a study powered to win on both progression-free and overall survival; it now concedes the melanoma trial narrowly failed.
Tone shiftQ4 FY2025 → Q2 FY2026Prefilled syringe decision pushed to year-end
An FDA decision was expected in late April; the agency did not act on either application, and management now aims for approval before the end of the year.
Tone shiftQ4 FY2025 → Q2 FY2026
Profitability & Financial Strength
In short: Margins and free cash flow are high and fund buybacks, while gross margin slipped on manufacturing problems.
Full Dupixent profit share starts in third quarter
Once the Sanofi development balance is repaid, Regeneron keeps its entire share of Dupixent profit, and collaboration revenue already grew 31.9% year over year.
Q2 FY2026 callOperating margin held at 30.1%
Profitability stayed near 30% while research spending climbed, showing the commercial business still covers the pipeline budget without straining the income statement.
Filed financialsAlmost all free cash flow returned to shareholders
Regeneron returned $3.7 billion over the past year, 98% of its free cash flow, mostly through buybacks that reduce the number of shares outstanding.
Filed financials
Limerick shutdown cut reported gross margin
A temporary halt in bulk manufacturing at the Irish plant pushed GAAP gross margin far below the 86.6% non-GAAP figure and forced management to lower its GAAP margin guidance.
Q2 FY2026 callResearch spending rises without late-stage wins
Management guides 2026 research spending to $5.9 billion to $6.1 billion, so costs climb even as programs like fianlimab fall short of their endpoints.
Q4 FY2025 call
Market Position
In short: Dupixent drives most profit, while EYLEA faces biosimilar entry and a key filler has drawn FDA citations.
Libtayo is now second in first-line lung cancer
Libtayo leads in non-melanoma skin cancer and is now the second most prescribed first-line lung cancer immunotherapy in the U.S., a third product carrying growth.
Q2 FY2026 callDupixent does not broadly suppress immunity
Management argues the drug blocks only the allergic inflammation pathway, which supports its safety record against oral and injected competitors pursuing the same diseases.
Q4 FY2025 callCemdisiran would be first siRNA in myasthenia gravis
Quarterly dosing under the skin differentiates it from infused C5 therapies and from FcRn drugs that a meaningful share of patients stop responding to over time.
Q2 FY2026 call
Aflibercept biosimilars accelerate EYLEA decline
Multiple biosimilar launches are expected in the second half of 2026, and total product revenue already grew only 0.7% year over year as EYLEA shrank.
Q2 FY2026 callPrefilled syringe depends on outside fillers
The complete response letter for the EYLEA HD prefilled syringe traced to unresolved inspection findings at a contract manufacturing site that Regeneron does not control.
Q3 FY2025 callMost-favored-nation pricing agreement
The agreement with the U.S. government ties American prices to lower prices charged abroad, which can reduce the net price Regeneron collects on its medicines.
Q1 FY2026 call